CROSSROADS STRATEGIES, LLC for EISAI, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Regulatory and legislative health care issues, including: 340B program; TRICARE Pharmacy Program; FDA Guidance on Alzheimer's drug development; Pharmaceutical Supply Chain; Drug Pricing; PDUFA Reauthorization. S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRITTANY JOHNSON HERNANDEZ | — |
| MATHEW LAPINSKI | — |
| JASON BENJAMIN VAN PELT | — |
Medicare/Medicaid MMM
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap; CMS NCD for Alzheimer's Drugs. H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376). H.R.4479/S.2609, Facilitating Innovative Nuclear Diagnostics Act of 2021.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRITTANY JOHNSON HERNANDEZ | — |
| MATHEW LAPINSKI | — |
| JASON BENJAMIN VAN PELT | — |
Trade (domestic/foreign) TRD
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRITTANY JOHNSON HERNANDEZ | — |
| MATHEW LAPINSKI | — |
| JASON BENJAMIN VAN PELT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.